{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:59:01Z","timestamp":1777784341207,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Artif Organs"],"published-print":{"date-parts":[[2009,10]]},"abstract":"\n Background\/Aims<\/jats:title>\n Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States. Telavancin's parenteral solution contains hydroxy propyl-\u03b2-cyclodextrin (HP-\u03b2-CD) to enhance its solubility. The disposition of telavancin and HP-\u03b2-CD during continuous renal replacement therapies (CRRT) has not been previously reported.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The transmembrane clearances (CLtm) of telavancin and HP-\u03b2-CD during continuous hemofiltration and hemodialysis were assessed using an in vitro bovine blood model with AN69 and polysulfone hemodiafilters at varying ultrafiltrate and dialysate flow rates (1, 2, 3, & 6 l\/hr).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The mean telavancin sieving coefficient ranged from 0.25 to 0.31 during continuous hemofiltration. At all ultrafiltration rates, no differences were observed in telavancin CLtm between the two hemodiafilter types. For continuous hemodialysis, mean telavancin saturation coefficients ranged from 0.10 to 0.43 and CLtm tended to be higher for the polysulfone hemodiafilter than the AN69 hemodiafilter, especially at higher flow rates. Mean HP-\u03b2-CD sieving coefficients ranged from 0.63 to 1.03 and saturation coefficients from 0.63 to 1.38, resulting in a CLtm that was similar to ultrafiltrate and dialysate flow rates.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Telavancin CLtm is dependent on hemodiafilter type, dialysate and ultrafiltration rates. CRRT with high ultrafiltrate or dialysate rates may result in sufficient telavancin clearance to alter telavancin dosing. HP-\u03b2-CD clearance by continuous hemodialysis or continuous hemofiltration is substantial and may be sufficient to prevent HP-\u03b2-CD accumulation in subjects receiving CRRT. Pharmacokinetic studies conducted in patients receiving CRRT and telavancin are needed to confirm these in vitro findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/039139880903201006","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T02:03:05Z","timestamp":1515722585000},"page":"745-751","source":"Crossref","is-referenced-by-count":15,"title":["Telavancin and Hydroxy Propyl-\u03b2-Cyclodextrin Clearance during Continuous Renal Replacement Therapy: An\n in vitro<\/i>\n Study"],"prefix":"10.1177","volume":"32","author":[{"given":"Jignesh H.","family":"Patel","sequence":"first","affiliation":[{"name":"University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences, Lexington, Kentucky - USA"},{"name":"Renal Replacement Therapy Kinetics Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariann D.","family":"Churchwell","sequence":"additional","affiliation":[{"name":"University of Toledo College of Pharmacy, Department of Pharmacy Practice, Toledo, Ohio - USA"},{"name":"Renal Replacement Therapy Kinetics Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie D.","family":"Seroogy","sequence":"additional","affiliation":[{"name":"Bioanalytical Chemistry, PharmacoFore, Inc., San Carlos, California - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Barriere","sequence":"additional","affiliation":[{"name":"Clinical & Medical Affairs, Theravance, Inc., South San Francisco, CA - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricor","family":"Grio","sequence":"additional","affiliation":[{"name":"Arnold Palmer Hospital for Children, Orlando, Florida - USA"},{"name":"Renal Replacement Therapy Kinetics Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Mueller","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Department of Clinical, Social & Administrative Sciences, Ann Arbor, Michigan - USA"},{"name":"Renal Replacement Therapy Kinetics Study Group"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"bibr1-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"bibr2-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"bibr3-039139880903201006","first-page":"514","volume-title":"Minutes of the 5th International Symposium on Cyclodextrins.","author":"Monbaliu J.","year":"1990"},{"key":"bibr4-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04465.x"},{"key":"bibr5-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G417"},{"key":"bibr6-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"bibr7-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1159\/000097078"},{"key":"bibr8-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1177\/039139880803101206"},{"key":"bibr9-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1159\/000420197"},{"key":"bibr10-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1186\/cc7093"},{"key":"bibr11-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1021\/js960075u"},{"key":"bibr12-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1208\/pt060243"},{"key":"bibr13-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1021\/js960213f"},{"key":"bibr14-039139880903201006","unstructured":"MesensJ.L., PuttemanP., VerheyenP. In: New trends in cyclodextrins and derivatives. DecheneD. (ed). Editions de Sant\u00e9: Paris; 1991. p 369\u2013407."},{"key":"bibr15-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70076-4"},{"key":"bibr16-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm352"},{"key":"bibr17-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-1083-8"},{"key":"bibr18-039139880903201006","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00858-07"},{"key":"bibr19-039139880903201006","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1525-1594.2007.00460.x","volume":"32","author":"Tian Q.","year":"2008","journal-title":"Int J Artif Organs"}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/039139880903201006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/039139880903201006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:40:31Z","timestamp":1777491631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/039139880903201006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1177\/039139880903201006"],"URL":"https:\/\/doi.org\/10.1177\/039139880903201006","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}